Loading
A phase 2 trial of Cyclophosphamide, Pembrolizumab in ovarian cancer and hepatocellular carcinoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), active and no longer recruiting.
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors is a phase 2 interventional study registered as NCT03836352 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 184 participants planned, started 2018-12-21 and due to reach its primary completion in 2023-12-31. Interventions recorded: DPX-Survivac, Cyclophosphamide, Pembrolizumab. Conditions listed: Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/